Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

Phase 2 Active not recruiting 64 enrolled Massachusetts General Hospital Medical College of Wisconsin · collab Ohio State University · collab Vanderbilt University · collab Washington University School of Medicine · collab

NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: • Ruxolitinib

Timeline

Start: 2017-11-03
Primary completion: 2026-12
Completion: 2026-12

Publications

DeFilipp Z, Kim HT, Knight LW, O'Connor SM, Dhaver SE, White M, Dholaria B, Schroeder MA, Vasu S, Abedin S, Chung J, El-Jawahri A, Frigault MJ, McAfee S, Newcomb RA, O'Donnell PV, Spitzer TR, Chen YB, Hobbs GS. Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood. 2025 May 15;145(20):2312-2316. doi: 10.1182/blood.2024028005.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	—	Oral

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

Summary

Timeline

Publications

Drugs

Indications